MedTrace Logo

Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy

NCT03330353 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2017-11-07

No results posted yet for this study

Summary

The specific aim of this study is to investigate rod, cone and melanopsin driven pupillary light response in individuals with progressive supranuclear palsy (PSP), age-matched healthy controls and individuals with other neurodegenerative diseases using chromatic pupillometry, with special interest in assessing melanopsin-driven post-illumination pupil response (PIPR) as an identifier for PSP.

The study addresses the following hypotheses:

1. Chromatic pupil responses, including rod/cone-driven rapid phase constriction and melanopsin-driven PIPR, are reduced in subjects with PSP compared to age-matched normal healthy control subjects,
2. Pupil parameters of the melanopsin-driven PIPR are abnormal in PSP subjects without supranuclear palsy, which is indicative of a subclinical physiological deficit of the OPN in the early stages of PSP.

If these hypotheses are upheld, chromatic pupillometry to measure the PIPR promises to be a reliable in vivo, non-invasive, convenient and inexpensive technique to detect asymptomatic pupillomotor impairment in advance of diagnostic oculomotor signs and deterioration of cognitive function.

Conditions

  • PSP - Progressive Supranuclear Palsy
  • PD - Parkinson's Disease
  • AD - Alzheimer's Disease
  • ALS (Amyotrophic Lateral Sclerosis)

Interventions

DIAGNOSTIC_TEST

Pupillometry

Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases

Sponsors & Collaborators

  • NeurOptics Inc.

    collaborator INDUSTRY

  • University of Toronto

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Shirley H Wray, MD, PhD · Massachusetts General Hospital

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2019-10-01
Completion
2019-10-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03330353 on ClinicalTrials.gov